ArticlePharmacoepidemiology and drug safety2022

Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists.

Cristina Rebordosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.